Alembic Pharmaceuticals Limited

BSE: 533573 NSE: APLLTD
Alembic Pharmaceuticals Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials and compliance.
CIN L24230GJ2010PLC061123 Incorporated 16 June 2010 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - NSE: APLLTD · BSE: 533573 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹7,344.9 Cr
▲ 10.08% YoY
EBITDA · FY 2026
₹1,172.87 Cr
▲ 11.62% YoY
Net profit · FY 2026
₹670.83 Cr
▲ 15.26% YoY
Authorised capital
₹40.5 Cr
Registered with MCA
Paid-up capital
₹39.31 Cr
Issued & subscribed
Open charges
₹600 Cr
Satisfied ₹219.36 Cr
Company age
16 yrs
Est. 2010
Employees · EPFO
15,822
Latest available

About Alembic Pharmaceuticals Limited

Data last updated: 20 December 2025

Alembic Pharmaceuticals Limited is a public limited company based in Vadodara, Gujarat, India, a subsidiary of Nirayu Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 16 June 2010, the company has been in operation for over 16 years.

Registered with ROC Ahmedabad under CIN L24230GJ2010PLC061123. Listed on BSE: 533573 and NSE: APLLTD.

Capital: an authorised share capital of ₹40.5 Cr and a paid-up capital of ₹39.31 Cr. Formerly known as Alembic Pharma Limited. It is led by directors including Ashok Kumar Barat and Geeta Amit Goradia.

Last AGM: 05 August 2025. Financial statements filed for year ended 31 March 2025. Office: Alembic Road, Vadodara, Gujarat, India – 390003.

As per the financials filed for FY 2025, the company reported a revenue of ₹6,714.63 Cr, a growth of 7% compared to the previous year.

The company has a workforce of approximately 15,822 employees as per the latest available data. It operates as a subsidiary of Nirayu Limited.

The company is associated with 2 brands - Alembic Pharmaceuticals, Alembic Limited. As per MCA filings, the company has open charges of ₹600 Cr and satisfied charges of ₹219.36 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alembicpharmaceuticals.com.

Company Details of Alembic Pharmaceuticals Limited
CIN L24230GJ2010PLC061123
Registration Number 061123
Incorporation Date 16 June 2010
ROC Ahmedabad
Listing Status Listed (BSE: 533573, NSE: APLLTD)
Company Status Active
Date of Last AGM 05 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Nirayu Limited
Compliance Status Active Compliant
Key People
Shaunak Chirayu Amin Managing Director Pranav Chirayu Amin Managing Director Rajkumar Shreeram Baheti Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    alembicpharmaceuticals.com
  • Social Media
  • Registered Address
    Alembic Road, Vadodara, Gujarat, India – 390003
  • Industry
    Pharma, API Manufacturers
Company report
Alembic Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Alembic Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Alembic Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24230GJ2010PLC061123. The current CIN is L24230GJ2010PLC061123, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230GJ2010PLC061123 Current
U24230GJ2010PLC061123 Previous

Associated Brands with Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited operates two associated brands: Alembic Pharmaceuticals and Alembic Limited. These brands represent Alembic Pharmaceuticals Limited's diversified market presence and brand portfolio.

Brand Description Website
Alembic Pharmaceuticals
Manufacturer & supplier of generic pharmaceuticals alembicpharmaceuticals.com
Alembic Limited
Active pharmaceutical ingredients are manufactured by Alembic. alembiclimited.com

Competitors & Alternatives of Alembic Pharmaceuticals Limited

Brands and companies operating in the same space as Alembic Pharmaceuticals Limited include Merck, Roivant Sciences, AbbVie and 7 more.

Competitor Description Location Founded
Merck Merck Pharmaceutical products are manufactured and marketed worldwide. Kenilworth, United Kingdom, United Kingdom 1891
Roivant Sciences Roivant Sciences Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. New York, United States, United States 2014
AbbVie AbbVie Biopharmaceutical research and drug development are conducted globally by AbbVie. Chicago, United States, United States 2012
Lilly Lilly Traditional pharmaceutical medicines are developed for multiple health fields. United States 1876
Gilead Gilead Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others Foster City, United States, United States 1987
United Therapeutics United Therapeutics Treatments for chronic and life-threatening diseases are developed and commercialized. Silver Spring, United States, United States 1998
Roche Roche Pharmaceuticals and diagnostics kits are developed for various diseases. Basel, Switzerland, Switzerland 1896
Ascendis Pharma Ascendis Pharma Long-acting prodrug therapies are developed for endocrine and rare diseases. Hellerup, Denmark, Denmark 2007
MorphoSys MorphoSys Therapeutic antibodies for cancer and other diseases are developed. Planegg, Germany, Germany 1992
Vertex Pharmaceuticals Vertex Pharmaceuticals Developer of drugs for the treatment of multiple disorders United States 1989

Business Activity of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is audited by M/s KKC & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s KKC & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is currently managed by 13 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ashok Kumar Barat
Also directs: Alembic Pharmaceuticals Limited, Bata India Ltd, Huhtamaki India Limited and 5 more
Director 10 Feb 2022 4 Years 4 Months Current
Geeta Amit Goradia
Also directs: Alembic Pharmaceuticals Limited, Jewel Consumer Care Private Limited
Director 03 Feb 2025 1 Years 5 Months Current
Shaunak Chirayu Amin
Also directs: Alembic Pharmaceuticals Limited, Fenix Research Labs Private Limited, Shreno Limited and 1 more
Managing Director 02 May 2013 13 Years 2 Months Current
Rajkumar Shreeram Baheti
Also directs: Alembic Pharmaceuticals Limited
Whole-Time Director 16 Jun 2010 16 Years 0 Months Current
Manisha Saraf
Also directs: Alembic Pharmaceuticals Limited, Baroda Industrial Development Corpn Limited
Nodal Officer 08 Apr 2023 3 Years 3 Months Current
Manish Santoshkumar Kejriwal
Also directs: Kedaara Capital Advisors Llp, Nish Capital Advisors Llp, Kedaara Capital Fund Ii Llp and 5 more
Director 31 Mar 2024 2 Years 3 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Alembic Pharmaceuticals Limited FY 2026 filings available

Alembic Pharmaceuticals Limited reported revenue of ₹7,344.9 Cr (up 10.08% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹7,344.9 Cr ▲ 10.08%
Profit · FY 2026
₹670.83 Cr ▲ 15.26%
EBITDA · FY 2026
₹1,172.87 Cr ▲ 11.62%
Revenue₹ Cr · Consolidated02,5005,0007,500FY 2020: ₹4,606 Cr4,606FY 2020FY 2021: ₹5,393 Cr · +17.1% YoY5,393+17.1%FY 2021FY 2022: ₹5,306 Cr · -1.6% YoY5,306-1.6%FY 2022FY 2023: ₹5,653 Cr · +6.5% YoY5,653+6.5%FY 2023FY 2024: ₹6,229 Cr · +10.2% YoY6,229+10.2%FY 2024FY 2025: ₹6,672 Cr · +7.1% YoY6,672+7.1%FY 2025FY 2026: ₹7,345 Cr · +10.1% YoY7,345+10.1%FY 2026
Net Profit₹ Cr · Consolidated05001,0001,500FY 2020: ₹801 Cr801FY 2020FY 2021: ₹1,147 Cr · +43.2% YoY1,146+43.2%FY 2021FY 2022: ₹521 Cr · -54.6% YoY521-54.6%FY 2022FY 2023: ₹342 Cr · -34.4% YoY342-34.4%FY 2023FY 2024: ₹616 Cr · +80.1% YoY616+80.1%FY 2024FY 2025: ₹582 Cr · -5.5% YoY582-5.5%FY 2025FY 2026: ₹671 Cr · +15.3% YoY671+15.3%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year01,0002,000Q1'25: ₹1,562 Cr · +5.1% YoY1,562+5.1%Q1'25Q2'25: ₹1,648 Cr · +3.3% YoY1,648+3.3%Q2'25Q3'25: ₹1,693 Cr · +3.8% YoY1,693+3.8%Q3'25Q4'25: ₹1,770 Cr · +16.7% YoY1,770+16.7%Q4'25Q1'26: ₹1,711 Cr · +9.5% YoY1,711+9.5%Q1'26Q2'26: ₹1,910 Cr · +15.9% YoY1,910+15.9%Q2'26Q3'26: ₹1,876 Cr · +10.8% YoY1,876+10.8%Q3'26Q4'26: ₹1,848 Cr · +4.4% YoY1,848+4.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹7,344.9 Cr ₹6,672.08 Cr ₹6,228.63 Cr ₹5,652.62 Cr ₹5,305.79 Cr ₹5,393.13 Cr ₹4,605.75 Cr
Other Income ₹54.41 Cr ₹42.55 Cr ₹28.31 Cr ₹2.74 Cr ₹50.46 Cr ₹10.02 Cr ₹4.94 Cr
Total Income ₹7,399.31 Cr ₹6,714.63 Cr ₹6,256.93 Cr ₹5,655.36 Cr ₹5,356.25 Cr ₹5,403.14 Cr ₹4,610.69 Cr
Cost of Materials Consumed ₹1,747.38 Cr ₹1,672.17 Cr ₹1,403.01 Cr ₹1,250.08 Cr ₹1,129.12 Cr ₹1,185.35 Cr ₹979.05 Cr
Purchases of Stock-in-Trade ₹508.88 Cr ₹410.96 Cr ₹454.91 Cr ₹380.09 Cr ₹360.5 Cr ₹265.92 Cr ₹270.93 Cr
Changes in Inventories -₹271.81 Cr -₹289.77 Cr -₹142.84 Cr ₹78.65 Cr -₹43.19 Cr -₹193.93 Cr -₹210.59 Cr
Employee Benefit Expense ₹1,731.93 Cr ₹1,562.34 Cr ₹1,446.3 Cr ₹1,169.13 Cr ₹1,133 Cr ₹1,051.17 Cr ₹906.44 Cr
Finance Costs ₹93.63 Cr ₹78.77 Cr ₹56.19 Cr ₹50.17 Cr ₹17.73 Cr ₹16.02 Cr ₹27.16 Cr
Depreciation & Amortisation ₹318.55 Cr ₹278.58 Cr ₹272.67 Cr ₹275.43 Cr ₹286.78 Cr ₹183.47 Cr ₹157.32 Cr
Other Expenses ₹2,510.06 Cr ₹2,308.15 Cr ₹2,133.9 Cr ₹2,066.33 Cr ₹1,852.2 Cr ₹1,527.06 Cr ₹1,436.89 Cr
Total Expenses ₹6,638.62 Cr ₹6,021.2 Cr ₹5,624.13 Cr ₹5,269.86 Cr ₹4,736.14 Cr ₹4,035.06 Cr ₹3,567.22 Cr
Profit Before Exceptional Items & Tax ₹760.69 Cr ₹693.43 Cr ₹632.81 Cr ₹385.51 Cr ₹620.11 Cr ₹1,368.08 Cr ₹1,043.48 Cr
Exceptional Items -₹66.98 Cr ₹12.87 Cr ₹0 ₹0 ₹0 ₹0 -₹43.65 Cr
Profit Before Tax ₹693.71 Cr ₹706.3 Cr ₹632.81 Cr ₹385.51 Cr ₹620.11 Cr ₹1,368.08 Cr ₹999.83 Cr
Total Tax Expense ₹23.12 Cr ₹125.16 Cr ₹16.01 Cr ₹12.6 Cr ₹104.46 Cr ₹253.32 Cr ₹199.18 Cr
Net Profit ₹670.83 Cr ₹582.01 Cr ₹615.82 Cr ₹341.99 Cr ₹520.94 Cr ₹1,146.5 Cr ₹800.7 Cr
  attributable to Owners - ₹583.42 Cr ₹615.82 Cr ₹341.99 Cr ₹545.68 Cr ₹1,178.11 Cr ₹828.82 Cr
  attributable to NCI ₹3.94 Cr -₹1.41 Cr ₹0 ₹0 -₹24.75 Cr -₹31.61 Cr -₹28.12 Cr
Other Comprehensive Income ₹24.87 Cr ₹5.53 Cr -₹10.84 Cr ₹13.37 Cr ₹1.4 Cr -₹3.69 Cr -₹1.82 Cr
Total Comprehensive Income ₹695.7 Cr ₹587.54 Cr ₹604.98 Cr ₹355.36 Cr ₹522.34 Cr ₹1,142.81 Cr ₹798.88 Cr
EBITDA (computed) ₹1,172.87 Cr ₹1,050.78 Cr ₹961.66 Cr ₹711.1 Cr ₹924.62 Cr ₹1,567.58 Cr ₹1,227.96 Cr
Basic EPS ₹34.33 ₹29.68 ₹31.33 ₹17.40 ₹27.76 ₹60.81 ₹43.97
Diluted EPS ₹34.33 ₹29.68 ₹31.33 ₹17.40 ₹27.76 ₹60.81 ₹43.97
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹8,762.59 Cr ₹7,772.94 Cr ₹6,445.58 Cr ₹6,182.83 Cr
Non-current Assets ₹4,189.99 Cr ₹3,685.14 Cr ₹3,367.03 Cr ₹3,272.81 Cr
Current Assets ₹4,542.6 Cr ₹4,087.8 Cr ₹3,078.56 Cr ₹2,910.02 Cr
Property, Plant & Equipment ₹2,843.59 Cr ₹2,523.53 Cr ₹2,546.71 Cr ₹2,398.45 Cr
Inventories ₹2,510.64 Cr ₹2,288.14 Cr ₹1,643.54 Cr ₹1,475.27 Cr
Trade Receivables ₹1,466.3 Cr ₹1,399.79 Cr ₹1,024.84 Cr ₹1,046.4 Cr
Cash & Equivalents ₹196.37 Cr ₹83.48 Cr ₹120.21 Cr ₹75.48 Cr
Equity (Net Worth) ₹5,668.98 Cr ₹5,189.52 Cr ₹4,818.2 Cr ₹4,370.47 Cr
Equity Share Capital ₹39.31 Cr ₹39.31 Cr ₹39.31 Cr ₹39.31 Cr
Borrowings (Non-current) ₹121.92 Cr ₹0 ₹0 ₹0
Borrowings (Current) ₹1,238.93 Cr ₹1,195.57 Cr ₹430.45 Cr ₹635.87 Cr
Total Debt (computed) ₹1,360.85 Cr ₹1,195.57 Cr ₹430.45 Cr ₹635.87 Cr
Current Liabilities ₹2,593.84 Cr ₹2,412.33 Cr ₹1,455 Cr ₹1,636.92 Cr
Total Liabilities ₹3,093.61 Cr ₹2,583.42 Cr ₹1,627.39 Cr ₹1,812.36 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹782.73 Cr ₹87.97 Cr ₹803.2 Cr ₹723.95 Cr ₹552.3 Cr
Investing Cash Flow -₹506.05 Cr -₹568.41 Cr -₹320.61 Cr -₹447.6 Cr -₹371.97 Cr
Financing Cash Flow -₹163.79 Cr ₹443.71 Cr -₹437.87 Cr -₹261.97 Cr -₹217.3 Cr
Capital Expenditure ₹434.62 Cr ₹563.62 Cr ₹327.47 Cr ₹443.41 Cr ₹425.64 Cr
Free Cash Flow (computed) ₹348.11 Cr -₹475.65 Cr ₹475.73 Cr ₹280.54 Cr ₹126.66 Cr
Dividends Paid ₹216.22 Cr ₹216.22 Cr ₹157.25 Cr ₹196.56 Cr ₹275.19 Cr
Net Change in Cash ₹112.89 Cr -₹36.73 Cr ₹44.73 Cr ₹14.39 Cr -₹36.97 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,847.72 Cr ₹1,876.31 Cr ₹1,910.15 Cr ₹1,710.72 Cr ₹1,769.64 Cr ₹1,692.74 Cr ₹1,647.98 Cr ₹1,561.73 Cr ₹1,516.98 Cr ₹1,630.57 Cr ₹1,594.93 Cr ₹1,486.15 Cr
Other Income ₹25.5 Cr ₹15.5 Cr ₹6.91 Cr ₹6.5 Cr ₹14.19 Cr ₹9.5 Cr ₹16.75 Cr ₹2.1 Cr ₹3.6 Cr ₹2.89 Cr ₹10.15 Cr ₹11.67 Cr
Total Income ₹1,873.22 Cr ₹1,891.81 Cr ₹1,917.06 Cr ₹1,717.22 Cr ₹1,783.83 Cr ₹1,702.25 Cr ₹1,664.72 Cr ₹1,563.83 Cr ₹1,520.58 Cr ₹1,633.46 Cr ₹1,605.09 Cr ₹1,497.81 Cr
Cost of Materials Consumed ₹404.24 Cr ₹448.73 Cr ₹463.14 Cr ₹431.27 Cr ₹426.2 Cr ₹446.91 Cr ₹393.14 Cr ₹405.93 Cr ₹337.38 Cr ₹317.58 Cr ₹413.87 Cr ₹334.19 Cr
Purchases of Stock-in-Trade ₹129.79 Cr ₹143.11 Cr ₹126.82 Cr ₹109.16 Cr ₹92.64 Cr ₹120.18 Cr ₹102.64 Cr ₹95.5 Cr ₹110.54 Cr ₹165.45 Cr ₹88.68 Cr ₹90.24 Cr
Changes in Inventories -₹1.88 Cr -₹62.87 Cr -₹74.04 Cr -₹133.02 Cr ₹11.77 Cr -₹127.55 Cr -₹66.66 Cr -₹107.34 Cr -₹68.55 Cr -₹22.27 Cr -₹41.12 Cr -₹10.91 Cr
Employee Benefit Expense ₹438.91 Cr ₹432.71 Cr ₹437.54 Cr ₹422.77 Cr ₹393.59 Cr ₹397.52 Cr ₹391.47 Cr ₹379.77 Cr ₹401.85 Cr ₹349.28 Cr ₹346.99 Cr ₹348.17 Cr
Finance Costs ₹22.56 Cr ₹23.31 Cr ₹24.23 Cr ₹23.52 Cr ₹24.52 Cr ₹22.26 Cr ₹18.81 Cr ₹13.18 Cr ₹10.94 Cr ₹15.17 Cr ₹15.69 Cr ₹14.39 Cr
Depreciation & Amortisation ₹88.58 Cr ₹80.12 Cr ₹76.07 Cr ₹73.77 Cr ₹68.99 Cr ₹70.05 Cr ₹70.51 Cr ₹69.04 Cr ₹69.48 Cr ₹69.45 Cr ₹67.56 Cr ₹66.18 Cr
Other Expenses ₹648.74 Cr ₹621.13 Cr ₹641 Cr ₹599.2 Cr ₹573.51 Cr ₹595.46 Cr ₹588.13 Cr ₹551.04 Cr ₹475.7 Cr ₹554.16 Cr ₹578.26 Cr ₹525.77 Cr
Total Expenses ₹1,730.94 Cr ₹1,686.24 Cr ₹1,694.76 Cr ₹1,526.67 Cr ₹1,591.22 Cr ₹1,524.82 Cr ₹1,498.03 Cr ₹1,407.12 Cr ₹1,337.34 Cr ₹1,448.83 Cr ₹1,469.94 Cr ₹1,368.03 Cr
Profit Before Exceptional Items & Tax ₹142.28 Cr ₹205.57 Cr ₹222.3 Cr ₹190.55 Cr ₹192.61 Cr ₹177.43 Cr ₹166.69 Cr ₹156.71 Cr ₹183.24 Cr ₹184.63 Cr ₹135.15 Cr ₹129.79 Cr
Exceptional Items -₹24.76 Cr -₹42.23 Cr ₹0 ₹0 ₹0 ₹0 ₹12.88 Cr ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹117.52 Cr ₹163.34 Cr ₹222.3 Cr ₹190.55 Cr ₹192.61 Cr ₹177.43 Cr ₹179.56 Cr ₹156.71 Cr ₹183.24 Cr ₹184.63 Cr ₹135.15 Cr ₹129.79 Cr
Total Tax Expense -₹82.91 Cr ₹29.55 Cr ₹40 Cr ₹36.47 Cr ₹35.31 Cr ₹40.09 Cr ₹27.28 Cr ₹22.49 Cr ₹4.64 Cr ₹4.13 Cr -₹1.92 Cr ₹9.16 Cr
Net Profit ₹201.54 Cr ₹131.95 Cr ₹183.71 Cr ₹153.63 Cr ₹156.63 Cr ₹137.7 Cr ₹153.15 Cr ₹134.54 Cr ₹178.21 Cr ₹180.46 Cr ₹136.56 Cr ₹120.6 Cr
  attributable to Owners - ₹132.97 Cr ₹184.71 Cr ₹154.38 Cr ₹156.89 Cr ₹138.42 Cr ₹153.41 Cr ₹134.71 Cr ₹178.21 Cr ₹180.46 Cr ₹136.56 Cr ₹120.6 Cr
  attributable to NCI ₹1.17 Cr -₹1.02 Cr -₹1 Cr -₹75.3 Lakh -₹26 Lakh -₹72 Lakh -₹26.2 Lakh -₹16.6 Lakh ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹11.53 Cr ₹7.95 Cr ₹4.67 Cr ₹70 Lakh ₹5.54 Cr ₹2.01 Cr ₹1.31 Cr -₹3.34 Cr -₹11.5 Cr ₹1.03 Cr ₹56.8 Lakh -₹93.7 Lakh
Total Comprehensive Income ₹213.07 Cr ₹139.9 Cr ₹188.38 Cr ₹154.33 Cr ₹162.17 Cr ₹139.71 Cr ₹154.46 Cr ₹131.21 Cr ₹166.71 Cr ₹181.49 Cr ₹137.13 Cr ₹119.66 Cr
EBITDA (computed) ₹253.42 Cr ₹309 Cr ₹322.6 Cr ₹287.84 Cr ₹286.12 Cr ₹269.73 Cr ₹256.01 Cr ₹238.93 Cr ₹263.66 Cr ₹269.25 Cr ₹218.4 Cr ₹210.36 Cr
Basic EPS ₹10.31 ₹6.76 ₹9.40 ₹7.85 ₹7.98 ₹7.01 ₹7.79 ₹6.85 ₹9.07 ₹9.18 ₹6.95 ₹6.14
Diluted EPS ₹10.31 ₹6.76 ₹9.40 ₹7.85 ₹7.98 ₹7.01 ₹7.79 ₹6.85 ₹9.07 ₹9.18 ₹6.95 ₹6.14
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹6,651.38 Cr ₹6,032.63 Cr ₹5,874.06 Cr ₹5,149 Cr ₹4,996.61 Cr ₹5,051.44 Cr ₹4,132.55 Cr
Other Income ₹55.9 Cr ₹47.88 Cr ₹31.32 Cr ₹3.55 Cr ₹49.98 Cr ₹9.73 Cr ₹134.75 Cr
Total Income ₹6,707.28 Cr ₹6,080.51 Cr ₹5,905.38 Cr ₹5,152.54 Cr ₹5,046.58 Cr ₹5,061.18 Cr ₹4,267.31 Cr
Cost of Materials Consumed ₹1,747.38 Cr ₹1,672.17 Cr ₹1,403.01 Cr ₹1,250.08 Cr ₹1,111.75 Cr ₹1,175.71 Cr ₹978.13 Cr
Purchases of Stock-in-Trade ₹394.57 Cr ₹385.14 Cr ₹449.7 Cr ₹337.21 Cr ₹353.35 Cr ₹279.33 Cr ₹244.26 Cr
Changes in Inventories -₹121.15 Cr -₹268.54 Cr -₹52.36 Cr ₹72.84 Cr ₹18.41 Cr -₹157.13 Cr -₹176.51 Cr
Employee Benefit Expense ₹1,612.91 Cr ₹1,466.57 Cr ₹1,335.91 Cr ₹1,094.82 Cr ₹1,028.18 Cr ₹948.27 Cr ₹806.37 Cr
Finance Costs ₹86.51 Cr ₹76.47 Cr ₹54.47 Cr ₹49 Cr ₹16.67 Cr ₹12.77 Cr ₹25.19 Cr
Depreciation & Amortisation ₹311 Cr ₹277.08 Cr ₹271.14 Cr ₹272.95 Cr ₹179.31 Cr ₹152.6 Cr ₹135.67 Cr
Other Expenses ₹1,954.96 Cr ₹1,875.9 Cr ₹1,739.28 Cr ₹1,729.71 Cr ₹1,430.45 Cr ₹1,233.03 Cr ₹1,077.4 Cr
Total Expenses ₹5,986.18 Cr ₹5,484.79 Cr ₹5,201.15 Cr ₹4,806.61 Cr ₹4,138.13 Cr ₹3,644.58 Cr ₹3,090.51 Cr
Profit Before Exceptional Items & Tax ₹721.1 Cr ₹595.72 Cr ₹704.23 Cr ₹345.93 Cr ₹908.45 Cr ₹1,416.6 Cr ₹1,176.79 Cr
Exceptional Items -₹66.99 Cr ₹12.87 Cr ₹0 ₹0 ₹0 ₹0 -₹10 Cr
Profit Before Tax ₹654.11 Cr ₹608.59 Cr ₹704.23 Cr ₹345.93 Cr ₹908.45 Cr ₹1,416.6 Cr ₹1,166.79 Cr
Total Tax Expense ₹13.69 Cr ₹105.47 Cr ₹37.75 Cr -₹79.5 Lakh ₹114.45 Cr ₹241.21 Cr ₹197.39 Cr
Net Profit ₹640.42 Cr ₹503.12 Cr ₹666.48 Cr ₹346.73 Cr ₹794 Cr ₹1,175.39 Cr ₹969.41 Cr
Other Comprehensive Income -₹3.68 Cr -₹1.07 Cr -₹14.62 Cr -₹34.6 Lakh -₹3.32 Cr -₹87.5 Lakh -₹9.33 Cr
Total Comprehensive Income ₹636.74 Cr ₹502.05 Cr ₹651.87 Cr ₹346.38 Cr ₹790.68 Cr ₹1,174.52 Cr ₹960.08 Cr
EBITDA (computed) ₹1,118.61 Cr ₹949.27 Cr ₹1,029.84 Cr ₹667.88 Cr ₹1,104.44 Cr ₹1,581.97 Cr ₹1,337.65 Cr
Basic EPS ₹32.58 ₹25.60 ₹33.91 ₹17.64 ₹40.39 ₹60.67 ₹51.42
Diluted EPS ₹32.58 ₹25.60 ₹33.91 ₹17.64 ₹40.39 ₹60.67 ₹51.42
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹8,151.25 Cr ₹7,556.27 Cr ₹6,398.54 Cr ₹6,130.42 Cr
Non-current Assets ₹4,120.24 Cr ₹3,790.07 Cr ₹3,409.99 Cr ₹3,350.2 Cr
Current Assets ₹4,001.01 Cr ₹3,766.2 Cr ₹2,988.55 Cr ₹2,780.22 Cr
Property, Plant & Equipment ₹2,828.42 Cr ₹2,513.47 Cr ₹2,535.66 Cr ₹2,377.45 Cr
Inventories ₹2,048.16 Cr ₹1,976.34 Cr ₹1,353.07 Cr ₹1,275.13 Cr
Trade Receivables ₹1,603.75 Cr ₹1,480.67 Cr ₹1,340.12 Cr ₹1,201.2 Cr
Cash & Equivalents ₹22.67 Cr ₹14.23 Cr ₹20.13 Cr ₹21.67 Cr
Equity (Net Worth) ₹5,615.26 Cr ₹5,194.74 Cr ₹4,908.91 Cr ₹4,414.3 Cr
Equity Share Capital ₹39.31 Cr ₹39.31 Cr ₹39.31 Cr ₹39.31 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹1,149.49 Cr ₹1,142.22 Cr ₹420.04 Cr ₹635.07 Cr
Total Debt (computed) ₹1,149.49 Cr ₹1,142.22 Cr ₹420.04 Cr ₹635.07 Cr
Current Liabilities ₹2,356.15 Cr ₹2,199.6 Cr ₹1,327.21 Cr ₹1,551.29 Cr
Total Liabilities ₹2,535.99 Cr ₹2,361.53 Cr ₹1,489.63 Cr ₹1,716.12 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹809.46 Cr ₹226.57 Cr ₹772.77 Cr ₹730.25 Cr ₹621.15 Cr
Investing Cash Flow -₹483.43 Cr -₹636.08 Cr -₹329.02 Cr -₹460.98 Cr -₹447.36 Cr
Financing Cash Flow -₹317.59 Cr ₹403.61 Cr -₹445.29 Cr -₹261.16 Cr -₹216.13 Cr
Capital Expenditure ₹431.97 Cr ₹563.02 Cr ₹324.52 Cr ₹443.26 Cr ₹408.11 Cr
Free Cash Flow (computed) ₹377.49 Cr -₹336.45 Cr ₹448.25 Cr ₹286.99 Cr ₹213.04 Cr
Dividends Paid ₹216.22 Cr ₹216.22 Cr ₹157.25 Cr ₹196.56 Cr ₹275.19 Cr
Net Change in Cash ₹8.44 Cr -₹5.9 Cr -₹1.54 Cr ₹8.11 Cr -₹42.34 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹1,718.74 Cr ₹1,642.24 Cr ₹1,796.24 Cr ₹1,494.17 Cr ₹1,570.64 Cr ₹1,406.09 Cr ₹1,580.35 Cr ₹1,475.56 Cr ₹1,474.55 Cr ₹1,588.39 Cr ₹1,478.84 Cr ₹1,332.27 Cr
Other Income ₹25.88 Cr ₹10.73 Cr ₹11.49 Cr ₹7.79 Cr ₹13.21 Cr ₹15.46 Cr ₹16.06 Cr ₹3.15 Cr ₹7.22 Cr ₹3.3 Cr ₹8.95 Cr ₹11.84 Cr
Total Income ₹1,744.62 Cr ₹1,652.97 Cr ₹1,807.73 Cr ₹1,501.96 Cr ₹1,583.85 Cr ₹1,421.55 Cr ₹1,596.41 Cr ₹1,478.7 Cr ₹1,481.78 Cr ₹1,591.69 Cr ₹1,487.8 Cr ₹1,344.12 Cr
Cost of Materials Consumed ₹404.24 Cr ₹448.73 Cr ₹463.14 Cr ₹431.27 Cr ₹426.2 Cr ₹446.91 Cr ₹393.14 Cr ₹405.93 Cr ₹337.38 Cr ₹317.58 Cr ₹413.87 Cr ₹334.19 Cr
Purchases of Stock-in-Trade ₹94.37 Cr ₹104.73 Cr ₹97.97 Cr ₹97.5 Cr ₹89.54 Cr ₹105.13 Cr ₹96.1 Cr ₹94.36 Cr ₹109.2 Cr ₹164.87 Cr ₹85.68 Cr ₹89.95 Cr
Changes in Inventories ₹16.32 Cr -₹48.77 Cr ₹22.8 Cr -₹111.5 Cr ₹34.06 Cr -₹173.73 Cr -₹17.19 Cr -₹111.68 Cr -₹25.25 Cr ₹10.15 Cr -₹30.07 Cr -₹7.2 Cr
Employee Benefit Expense ₹407.02 Cr ₹401.36 Cr ₹408.12 Cr ₹396.4 Cr ₹373.27 Cr ₹369.18 Cr ₹367.61 Cr ₹356.51 Cr ₹354.92 Cr ₹327.11 Cr ₹326.41 Cr ₹327.47 Cr
Finance Costs ₹19.42 Cr ₹21.65 Cr ₹22.81 Cr ₹22.64 Cr ₹23.71 Cr ₹21.79 Cr ₹18.28 Cr ₹12.69 Cr ₹10.13 Cr ₹14.66 Cr ₹15.39 Cr ₹14.29 Cr
Depreciation & Amortisation ₹82.31 Cr ₹79.67 Cr ₹75.64 Cr ₹73.37 Cr ₹68.59 Cr ₹69.69 Cr ₹70.12 Cr ₹68.68 Cr ₹69.12 Cr ₹69.08 Cr ₹67.18 Cr ₹65.75 Cr
Other Expenses ₹522.72 Cr ₹464.59 Cr ₹500.9 Cr ₹466.76 Cr ₹476.92 Cr ₹478.78 Cr ₹481.2 Cr ₹439.01 Cr ₹410.11 Cr ₹431.53 Cr ₹475.5 Cr ₹422.13 Cr
Total Expenses ₹1,546.4 Cr ₹1,471.96 Cr ₹1,591.38 Cr ₹1,376.44 Cr ₹1,492.29 Cr ₹1,317.74 Cr ₹1,409.26 Cr ₹1,265.5 Cr ₹1,265.61 Cr ₹1,334.99 Cr ₹1,353.95 Cr ₹1,246.59 Cr
Profit Before Exceptional Items & Tax ₹198.22 Cr ₹181.01 Cr ₹216.35 Cr ₹125.52 Cr ₹91.56 Cr ₹103.81 Cr ₹187.15 Cr ₹213.2 Cr ₹216.16 Cr ₹256.7 Cr ₹133.84 Cr ₹97.53 Cr
Exceptional Items -₹24.76 Cr -₹42.23 Cr ₹0 ₹0 ₹0 ₹0 ₹12.88 Cr ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹173.46 Cr ₹138.78 Cr ₹216.35 Cr ₹125.52 Cr ₹91.56 Cr ₹103.81 Cr ₹200.02 Cr ₹213.2 Cr ₹216.16 Cr ₹256.7 Cr ₹133.84 Cr ₹97.53 Cr
Total Tax Expense -₹69.61 Cr ₹24.31 Cr ₹36.99 Cr ₹22 Cr ₹16.22 Cr ₹18 Cr ₹34.24 Cr ₹37.01 Cr ₹14.29 Cr ₹23.46 Cr ₹0 ₹0
Net Profit ₹243.07 Cr ₹114.47 Cr ₹179.36 Cr ₹103.52 Cr ₹75.34 Cr ₹85.81 Cr ₹165.78 Cr ₹176.19 Cr ₹201.87 Cr ₹233.24 Cr ₹133.84 Cr ₹97.53 Cr
Other Comprehensive Income ₹44 Lakh ₹2.19 Cr -₹5.92 Cr -₹39 Lakh ₹1.82 Cr ₹10.8 Lakh ₹21.6 Lakh -₹3.22 Cr -₹12.68 Cr ₹16.2 Lakh -₹2.01 Cr -₹8.6 Lakh
Total Comprehensive Income ₹243.51 Cr ₹116.66 Cr ₹173.44 Cr ₹103.13 Cr ₹77.16 Cr ₹85.92 Cr ₹166 Cr ₹172.97 Cr ₹189.19 Cr ₹233.41 Cr ₹131.83 Cr ₹97.44 Cr
EBITDA (computed) ₹299.95 Cr ₹282.33 Cr ₹314.8 Cr ₹221.53 Cr ₹183.86 Cr ₹195.29 Cr ₹275.55 Cr ₹294.57 Cr ₹295.41 Cr ₹340.45 Cr ₹216.41 Cr ₹177.57 Cr
Basic EPS ₹12.37 ₹5.82 ₹9.12 ₹5.27 ₹3.83 ₹4.37 ₹8.43 ₹8.96 ₹10.27 ₹11.87 ₹6.81 ₹4.96
Diluted EPS ₹12.37 ₹5.82 ₹9.12 ₹5.27 ₹3.83 ₹4.37 ₹8.43 ₹8.96 ₹10.27 ₹11.87 ₹6.81 ₹4.96
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Alembic Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Alembic Pharmaceuticals Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 69.74%, foreign institutional investors hold 4.25%, domestic institutional investors hold 16.18%, retail and other public shareholders hold 9.83% of Alembic Pharmaceuticals Limited. The company had 86,432 shareholders on record.

Promoters: 69.74%DII (Domestic Institutional): 16.18%FII (Foreign Institutional): 4.25%Retail & Others: 9.83%
Mar 2026
QUARTER
69.74% Promoters
16.18% DII (Domestic Institutional)
4.25% FII (Foreign Institutional)
9.83% Retail & Others
Promoter holding - history
Now 69.74% · Mar 2026High 74.35% · Sep 2016Low 69.48% · Mar 2021
68%70%72%74%76%Dec 2015Jun 2018Sep 2020Mar 2023Sep 2025Dec 2015: 74.13%Mar 2016: 74.13%Jun 2016: 74.13%Sep 2016: 74.35%Dec 2016: 72.68%Mar 2017: 72.68%Jun 2017: 72.68%Sep 2017: 72.68%Dec 2017: 72.68%Mar 2018: 72.93%Jun 2018: 72.96%Sep 2018: 72.96%Dec 2018: 72.96%Mar 2019: 72.97%Jun 2019: 72.97%Sep 2019: 72.97%Dec 2019: 72.97%Mar 2020: 72.97%Jun 2020: 72.97%Aug 2020: 69.98%Sep 2020: 69.77%Dec 2020: 69.78%Mar 2021: 69.48%Jun 2021: 69.48%Sep 2021: 69.48%Dec 2021: 69.48%Mar 2022: 69.61%Jun 2022: 69.61%Sep 2022: 69.61%Dec 2022: 69.61%Mar 2023: 69.61%Jun 2023: 69.61%Sep 2023: 69.61%Dec 2023: 69.61%Mar 2024: 69.61%Jun 2024: 69.61%Sep 2024: 69.61%Dec 2024: 69.61%Mar 2025: 69.67%Jun 2025: 69.67%Sep 2025: 69.74%Dec 2025: 69.74%Mar 2026: 69.74%74.35%69.48%69.74%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters69.74%69.74%69.74%69.67%69.67%69.61%
Public30.26%30.26%30.26%30.33%30.33%30.39%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters69.74%69.67%69.61%69.61%69.61%69.48%72.97%72.97%72.93%72.68%74.13%
Public30.26%30.33%30.39%30.39%30.39%30.52%27.03%27.03%27.07%27.32%25.87%
Promoter change (YoY, %pts)+0.07+0.06+0.00+0.00+0.13-3.49+0.00+0.04+0.25-1.45-

Board & Governance of Alembic Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Alembic Pharmaceuticals Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Chirayu Ramanbhai Amin.

DirectorPositionOn board sinceListed boards
Chirayu Ramanbhai Amin Executive Director · CEO · Chairperson 2010-06-16 3
Pranav Chirayu Amin Executive Director · MD 2011-03-31 3
Shaunak Chirayu Amin Executive Director · MD 2013-05-02 1
Ashok Kumar Barat Non-Executive - Independent Director 2022-02-10 7
Jai Shishir Diwanji Non-Executive - Independent Director 2023-05-05 5
Manish Santoshkumar Kejriwal Non-Executive - Independent Director 2024-03-31 4
Geeta Amit Goradia Non-Executive - Independent Director 2025-02-03 1
Raj Kumar Baheti Executive Director 2010-06-16 1
Board Committees
CommitteeMembers
Audit Committee Ashok Kumar Barat (Chairperson), Jai Shishir Diwanji, Geeta Amit Goradia
Nomination and remuneration committee Manish Santoshkumar Kejriwal (Chairperson), Ashok Kumar Barat, Jai Shishir Diwanji, Geeta Amit Goradia
Stakeholders Relationship Committee Jai Shishir Diwanji (Chairperson), Pranav Chirayu Amin, Raj Kumar Baheti
Risk Management Committee Ashok Kumar Barat (Chairperson), Pranav Chirayu Amin, Raj Kumar Baheti
Corporate Social Responsibility Committee Chirayu Ramanbhai Amin (Chairperson), Ashok Kumar Barat, Manish Santoshkumar Kejriwal

Group Structure of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Alembic Pharmaceuticals Limited's business expansion strategy and organizational complexity.

1
Associated companies

Charges & Borrowings of Alembic Pharmaceuticals Limited

Open charges
₹600 Cr
Satisfied charges
₹219.36 Cr
Breakdown by lending institutions
Others₹600.00 Cr
Latest charge details
DateLenderAmountStatus
30 Jun 2011 Others ₹600 Cr Open
19 Nov 2021 Hdfc Bank Limited ₹5 Cr Satisfied
26 Jul 2021 Yes Bank Limited ₹10 Cr Satisfied
08 May 2014 Bank of Baroda ₹1.36 Cr Satisfied
02 Dec 2011 Dbs Bank Limited ₹78 Cr Satisfied

Total charge records: 8 View all charges

Employees and EPFO Compliance at Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has a workforce of 15,822 employees as of Feb 11, 2025.

Employee count
15,822
Active EPFO establishments
1
Employee growth
3.66%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Alembic Pharmaceuticals Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Alembic Pharmaceuticals Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Alembic Pharmaceuticals Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Alembic Pharmaceuticals Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Alembic Pharmaceuticals Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Alembic Pharmaceuticals Limited

MSME Payment Delays by Alembic Pharmaceuticals Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Alembic Pharmaceuticals Limited

Subsidiaries & Group Companies of Alembic Pharmaceuticals Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Alembic Pharmaceuticals Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Alembic Pharmaceuticals Limited

MCA Filings & Documents of Alembic Pharmaceuticals Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Alembic Pharmaceuticals Limited

Activity
05 Aug 2025
Alembic Pharmaceuticals Limited last Annual general meeting of members was held on 05 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Alembic Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Directors
03 Feb 2025
Geeta Amit Goradia was appointed as a Director on 03 Feb 2025 & has been associated with this company since 1 year 5 months.
Directors
31 Mar 2024
Manish Santoshkumar Kejriwal was appointed as a Director on 31 Mar 2024 & has been associated with this company since 2 years 3 months.
Charges
13 Jun 2023
A charge registered on 26 Jul 2021 via Charge ID 100469987 with Yes Bank Limited was fully satisfied on 13 Jun 2023.
Directors
05 May 2023
Jai Shishir Diwanji was appointed as a Director on 05 May 2023 & has been associated with this company since 3 years 2 months.

Recent News on Alembic Pharmaceuticals Limited

Frequently Asked Questions about Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 16 June 2010 (16+ years old) and is registered under CIN L24230GJ2010PLC061123. Listed on BSE: 533573 and NSE: APLLTD. The company has 15,822 employees.

Alembic Pharmaceuticals Limited reported revenue of ₹6,714.63 Cr for FY 2025 (up 7.00% YoY).

The current directors of Alembic Pharmaceuticals Limited are:

The primary industry of Alembic Pharmaceuticals Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Alembic Pharmaceuticals Limited is listed on both BSE (code: 533573) and NSE (symbol: APLLTD).

Alembic Pharmaceuticals Limited can be reached at the registered office: Alembic Road, Vadodara, Gujarat, India – 390003, or through the website alembicpharmaceuticals.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available